These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9106175)

  • 1. Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy.
    Ragnhammar P; Wadhwa M
    Med Oncol; 1996 Sep; 13(3):161-6. PubMed ID: 9106175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF.
    Wadhwa M; Mellstedt H; Small E; Thorpe R
    Dev Biol (Basel); 2003; 112():61-7. PubMed ID: 12762505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.
    Wadhwa M; Bird C; Fagerberg J; Gaines-Das R; Ragnhammar P; Mellstedt H; Thorpe R
    Clin Exp Immunol; 1996 May; 104(2):351-8. PubMed ID: 8625532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma.
    Spitler LE; Cao H; Piironen T; Whiteside TL; Weber RW; Cruickshank S
    Am J Clin Oncol; 2017 Apr; 40(2):207-213. PubMed ID: 25286079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine refacing effect reduces granulocyte macrophage colony-stimulating factor susceptibility to antibody neutralization.
    Heinzelman P; Carlson SJ; Cox GN
    Protein Eng Des Sel; 2015 Oct; 28(10):461-6. PubMed ID: 25855658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
    Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
    Clin Cancer Res; 1999 Jun; 5(6):1353-61. PubMed ID: 10389919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of neutralising antibodies restricts the use of human granulocyte/macrophage colony stimulating factor for vaccine studies in rhesus macaques.
    Eisenblätter M; Stahl-Hennig C; Kuate S; Stolte N; Jasny E; Hahn H; Pope M; Tenner-Racz K; Racz P; Steinman RM; Uberla K; Ignatius R
    Vaccine; 2004 Sep; 22(25-26):3295-302. PubMed ID: 15308352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
    Liljefors M; Nilsson B; Mellstedt H; Frödin JE
    Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial cells are the major source of biologically active granulocyte macrophage colony-stimulating factor in human endometrium.
    Giacomini G; Tabibzadeh SS; Satyaswaroop PG; Bonsi L; Vitale L; Bagnara GP; Strippoli P; Jasonni VM
    Hum Reprod; 1995 Dec; 10(12):3259-63. PubMed ID: 8822455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Reising S; Repasky EA; Czuczman MS
    Leuk Lymphoma; 2005 Dec; 46(12):1775-84. PubMed ID: 16263581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte-macrophage colony-stimulating factor mimicry and receptor interactions.
    Von Feldt JM; Monfardini C; Kieber-Emmons T; Voet D; Weiner DB; Williams WV
    Immunol Res; 1994; 13(2-3):96-109. PubMed ID: 7539825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).
    Rini B; Wadhwa M; Bird C; Small E; Gaines-Das R; Thorpe R
    Cytokine; 2005 Jan; 29(2):56-66. PubMed ID: 15598439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease.
    Meager A; Wadhwa M; Bird C; Dilger P; Thorpe R; Newsom-Davis J; Willcox N
    Immunology; 1999 Jul; 97(3):526-32. PubMed ID: 10447777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation.
    Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; OIsterborg A; Thorpe R; Mellstedt H; Wadhwa M
    Clin Immunol; 2001 Apr; 99(1):65-74. PubMed ID: 11286542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation.
    Cook AD; Louis C; Robinson MJ; Saleh R; Sleeman MA; Hamilton JA
    Arthritis Res Ther; 2016 Dec; 18(1):287. PubMed ID: 27908288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
    Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
    Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of serum deprivation on constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells.
    Uemura Y; Kobayashi M; Nakata H; Harada R; Kubota T; Taguchi H
    Int J Cancer; 2004 May; 109(6):826-32. PubMed ID: 15027115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
    Fukuda M; Horibe K; Furukawa K
    Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-10 inhibits burst-forming unit-erythroid growth by suppression of endogenous granulocyte-macrophage colony-stimulating factor production from T cells.
    Oehler L; Kollars M; Bohle B; Berer A; Reiter E; Lechner K; Geissler K
    Exp Hematol; 1999 Feb; 27(2):217-23. PubMed ID: 10029159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1 and interleukin-2 control granulocyte- and granulocyte-macrophage colony-stimulating factor gene expression and cell proliferation in cultured acute myeloblastic leukemia.
    Cozzolino F; Torcia M; Bettoni S; Aldinucci D; Burgio VL; Petti MC; Rubartelli A; Barbui T; Rambaldi A
    Int J Cancer; 1990 Nov; 46(5):902-7. PubMed ID: 1699903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.